Global Submucosal Injections Market Size study & Forecast, by Type of Agent (Normal saline, Dextrose water, Hydroxyethyl starch, Hydroxypropyl methylcellulose, Succinylated gelatin, Hyaluronic acid, Others), By Application (Colorectal Cancer, Gastric Canc

Global Submucosal Injections Market Size study & Forecast, by Type of Agent (Normal saline, Dextrose water, Hydroxyethyl starch, Hydroxypropyl methylcellulose, Succinylated gelatin, Hyaluronic acid, Others), By Application (Colorectal Cancer, Gastric Cancer, Esophageal Cancer), By End User (Hospitals, Surgical Centers, Others), and Regional Analysis, 2023-2030

Global Submucosal Injections Market is valued at approximately USD 1.23 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5.8% over the forecast period 2023-2030. Submucosal injection is a medical technique that involves injecting drugs or other therapeutic substances into a tissue or organ's submucosal layer. The submucosal layer is the layer of tissue that lies just below the mucous membrane, which lines the inner surface of various organs, such as the gastrointestinal tract, respiratory tract, and urinary tract. Submucosal injections are commonly used in medical and surgical procedures for diagnostic, therapeutic, or palliative purposes. The rising incidences of cancer, the surge in the number of endoscopic mucosal resection procedures, increasing favorable reimbursement policies, and the development of the healthcare sector are the key driving factors for market growth across the globe.

In addition, the rising preference towards minimally invasive procedures is playing a vital role in stipulating market growth across the globe. Submucosal injections are minimally invasive procedures that offer advantages such as reduced postoperative complications, faster recovery, and shorter hospital stays. According to Statista, the worldwide revenue for minimally invasive surgery reached around USD 20.5 billion in 2019. This amount is also anticipated to increase and is expected to reach about USD 44.04 billion by 2030. As the trend towards minimally invasive procedures continues to gain traction, the demand for submucosal injections as part of these procedures is expected to increase during the estimated period. Moreover, the rising adoption of advanced technology in healthcare, as well as the rising focus on early diagnosis and intervention present various lucrative opportunities over the forecasting years. However, the unavailability of skilled healthcare professionals and the presence of alternative treatment options are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Submucosal Injections Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising endoscopic mucosal resection procedures, and the presence of well-established healthcare facilities. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, increasing healthcare expenditure, and Increased application of submucosal injections in the market space.

Major market player included in this report are:
Bio Space Inc.
Cosmo Pharmaceuticals N.V.
FUJIFILM Medical Systems
Medtronic Plc.
Zeon Medical Inc.
Boston Scientific Corporation
Aries Pharmaceuticals
Sumitomo Bakelite Company Limited
ERBE Elektromedizin GmbH
Ovesco Endoscopy AG

Recent Developments in the Market:
 In September 2022, Olympus announced that the USA distribution of EndoClot Submucosal Injection Solution and EndoClot Polysaccharide Hemostatic Spray, which is designed by Endoclot Plus Inc.

Global Submucosal Injections Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Type of Agent, Application, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type of Agent:
Normal saline
Dextrose water
Hydroxyethyl starch
Hydroxypropyl methylcellulose
Succinylated gelatin
Hyaluronic acid
Others

By Application:
Colorectal Cancer
Gastric Cancer
Esophageal Cancer

By End User:
Hospitals
Surgical Centers
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned

Bio Space Inc.
Cosmo Pharmaceuticals N.V.
FUJIFILM Medical Systems
Medtronic Plc.
Zeon Medical Inc.
Boston Scientific Corporation
Aries Pharmaceuticals
Sumitomo Bakelite Company Limited
ERBE Elektromedizin GmbH
Ovesco Endoscopy AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.